Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ALT |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 415.3M |
| IPO Year | 1998 | N/A |
| Metric | OSPN | ALT |
|---|---|---|
| Price | $11.15 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.00 | $16.00 |
| AVG Volume (30 Days) | 476.8K | ★ 5.6M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 99.92 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $241,436,000.00 | $20,000.00 |
| Revenue This Year | $0.69 | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $2.90 |
| 52 Week High | $20.37 | $7.73 |
| Indicator | OSPN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 55.36 |
| Support Level | $11.26 | $5.19 |
| Resistance Level | $12.21 | $5.75 |
| Average True Range (ATR) | 0.52 | 0.57 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 38.16 | 49.59 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.